Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CRYZ | Q08257 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 4-Hydroxycyclophosphamide SCHEMBL17737224 | 0.82 | NPSR1 (0.54) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| 4-Hydroxycyclophosphamide SCHEMBL406857 | 0.82 | NPSR1 (0.54) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| SCHEMBL12451557 | 0.80 | NPSR1 (0.49) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| SCHEMBL17897696 | 0.80 | NPSR1 (0.49) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| SCHEMBL10412920 | 0.80 | NPSR1 (0.53) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| SCHEMBL17635575 | 0.78 | NPSR1 (0.50) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| SCHEMBL10413698 | 0.78 | NPSR1 (0.47) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Perfosfamide SCHEMBL1650261 | 0.77 | NPSR1 (0.49) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Perfosfamide SCHEMBL4652 | 0.77 | NPSR1 (0.49) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| SCHEMBL17897647 | 0.77 | NPSR1 (0.46) | NPSR1KDM4EALOX15MAPK1CRYZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160193347-A1 | MULTI-TARGETED UBENIMEX PRODRUG DERIVATIVE AND PREPARATION METHOD AND USE THEREOF | WEIFANG BOCHUANG INTERNATIONAL ACADEMY OF BIOTECHNOLOGY AND MEDICINE (CN) | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193347-A1 | MULTI-TARGETED UBENIMEX PRODRUG DERIVATIVE AND PREPARATION METHOD AND USE THEREOF | ANPEP, DNPEP, ENPEP | NPSR1 1622/4885KDM4E 1194/4885ALOX15 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.